This study will help determine the feasibility and acceptability of a brief opioid-informed alcohol intervention in patients receiving prescribed buprenorphine for opioid use who are currently drinking alcohol. It will also provide initial information on whether the intervention improves outcomes related to alcohol use. The results of this proof-of-concept study will inform whether a future larger clinical trial is warranted.
Participants must be taking prescribed buprenorphine for at least 2 weeks
Participants must be 18 years or older.
Meet DSM-5 criteria for alcohol use disorder (AUD)
Participants must report alcohol use ≥ 1 day/week on average in the past 28 days
Currently receiving formal alcohol use treatment.
Currently experiencing psychosis
University of Notre Dame
Lead sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Collaborator